No Data
Japanese stock buybacks this week (2/24~2/28)
――――2/25――――$Saint Marc Holdings(3395.JP)$ will buy back up to 2.82 million shares, 13.8% of its outstanding shares (excluding its own shares), for an amount of JPY¥ 6.5 billion.$Riken Vitamin(4526.
Asahi Yukizai Cuts Earnings Forecast for Fiscal 2025
Asahi Yukizai to Introduce 'CxO System' for Governance, Growth Strategy
＜Today's Individual Materials＞ EED, Kyoken Pharmaceuticals, Asahi Organic Materials, WACUL ETC (Announcement on the 26th)
▽ EID <6038.T>, revised the ordinary Dividends to 16 yen at the end of the fiscal year in June 2025, adding a commemorative Dividends of 6 yen for the 25th anniversary, making a total of 22 yen (the previous period had an ordinary Dividends of 14 yen). At the same time, a commemorative Shareholder benefit will be implemented, presenting a Quo Card worth 10,000 yen to Shareholders holding 500 shares or more. ▽ Kaken Pharmaceutical <4521.T> set a maximum acquisition limit of 1.8 million shares (4.52% of the total issued shares excluding treasury stock) and a 9 billion yen share buyback limit, and as of May 30, 1.8 million shares (3.91% of the issued shares before cancellation) were canceled. ▽
Research drugs, etc., Share Buyback announcement on February 26.
The stocks for which share buyback frameworks were announced on February 26 (Wednesday) are as follows: <4521> Kyowa Hakko Kirin 1.8 million shares (4.5%) 9 billion yen (from February 27, 2025 to September 30, 2025) <4527> Rohto Pharmaceutical 2.43 million shares (1.1%) 5 billion yen (from February 27, 2025 to April 30, 2025) <2212> Yamazaki Baking 1.5 million shares (0.8%) 4.1 billion 43 million yen (on February 27, 2025) <6524> Hokuriku Industrial 1.2 million shares (4.5%) 2.7 billion 16.8 million yen (from February 27, 2025 to ...
Asahi Organic Chemicals has revised its operating profit downwards on March 25, from 12 billion yen to 10.5 billion yen.
Asahi Organic Chemicals announced a revision of its Financial Estimates for the fiscal year ending March 2025. Revenue has been revised down from 87 billion yen to 84 billion yen and operating profit from 12 billion yen to 10.5 billion yen. This is due to the postponement and review of semiconductor-related projects in the pipe system business, as well as a decrease in sales volume of base material products in the resin business, which indicates that the estimates will likely fall short of the previous announcement. 【Positive Evaluation】<1723> Nippon Dengi Revision | 【Negative Evaluation】<9885> Sharure Revision | <